Table 2.

Cardiac biomarker levels in the overall study population, survivors and non-survivors, stratified by concomitant cardiac disease.

	Biomarkers	Early stage			Late stage
		Non-cardiac disease	Cardiac disease	p	Non-cardiac disease	Cardiac disease	p
All included patients		n = 897	n = 126		n = 897	n = 126
	Hs-TnI (pg/mL)	2.7 (1.9–7.5)	8.7 (3.3–20.9)	<0.001	2.1 (1.9–4.9)	6.9 (2.7–20.9)	<0.001
	CK-MB (ng/mL)	0.7 (0.5–1.1)	1.1 (0.7–1.9)	<0.001	0.6 (0.4–0.9)	1.0 (0.5–1.6)	<0.001
	Myo (ng/mL)	34.9 (26.0–57.4)	53.7 (33.6–93.4)	<0.001	29.8 (23.4–41.2)	38.1 (27.4–60.2)	<0.001
	NT-proBNP (pg/mL)	80.0 (30.0–198.5)	352.5 (109.5–1291.5)	<0.001	63.0 (26.0–156.5)	267.5 (82.3–1198.8)	<0.001
Alive		n = 854	n = 109		n = 854	n = 109
	Hs-TnI (pg/mL)	2.5 (1.9–6.5)	7.6 (3.1–19.7)	<0.001	1.9 (1.9–4.3)	5.3 (2.5–13.0)	<0.001
	CK-MB (ng/mL)	0.7 (0.5–1.1)	1.1 (0.7–1.9)	<0.001	0.6 (0.4–0.8)	0.9 (0.5–1.3)	<0.001
	Myo (ng/mL)	34.3 (25.7–53.2)	47.5 (32.3–76.2)	<0.001	29.1 (23.1–38.5)	33.8 (25.0–50.2)	0.002
	NT-proBNP (pg/mL)	72.0 (29.0–173.5)	257.0 (94.0–1101.0)	<0.001	57.0 (25.0–134.3)	169.0 (65.5–533.5)	<0.001
Died		n = 43	n = 17		n = 43	n = 17
	Hs-TnI (pg/mL)	35.3 (5.5–296.4)	16.7 (9.4–53.2)	0.337	156.1 (32.6–523.5)	107.4 (29.2–748.7)	0.658
	CK-MB (ng/mL)	2.9 (1.2–4.6)	1.0 (0.5–2.4)	0.007	4.5 (2.1–10.2)	6.4 (1.7–11.6)	0.688
	Myo (ng/mL)	174.1 (108.4–368.6)	101.9 (76.2–197.6)	0.070	869.8 (368.6–1200.0)	587.3 (211.5–1200.0)	0.416
	NT-proBNP (pg/mL)	1032.0 (359.0–3122.0)	991.0 (676.0–2970.5)	0.583	4985.0 (1824.0–10957.0)	2596.0 (1207.5–12869.5)	0.528

p values were calculated between the cardiac and non-cardiac groups by Mann-Whitney U test.

Hs-TnI, High sensitivity troponin-I; CK-MB, creatine kinase-MB; Myo, myoglobin; NT-proBNP, N terminal pro B type natriuretic peptide. The bold p values mean that they are of significance in statistics.